WOLVERINE 20

BPC-157 + TB-500 (20mg Blend) Dosage Protocol

BPC-157 + TB-500 (20 mg Blend) Dosage Protocol

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide fragment derived from human gastric juice, studied for its cytoprotective and tissue-repair properties across gastrointestinal, musculoskeletal, and neurological systems^[1]^[2]. TB-500 (Thymosin β4) is a 43-amino-acid peptide involved in cell migration, angiogenesis, and wound healing^[3]^[4]. This blend combines both peptides for synergistic tissue-repair research applications.

Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL total concentration (~3.33 mg/mL of each peptide).
Typical daily range: 250–500 mcg BPC-157 + 250–500 mcg TB-500 (500–1,000 mcg total blend) once daily.
Easy measuring: At 6.67 mg/mL total, 1 unit = 0.01 mL ≈ 66.7 mcg total (~33.3 mcg of each peptide) on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 14 days.

Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~6.67 mg/mL total)

Week	Daily Dose (total blend)	Per-Peptide Dose	Units (mL)
Weeks 1–2	500 mcg (0.5 mg)	~250 mcg each	7.5 units (0.075 mL)
Weeks 3–4	666 mcg (0.67 mg)	~333 mcg each	10 units (0.10 mL)
Weeks 5–8	1,000 mcg (1.0 mg)	~500 mcg each	15 units (0.15 mL)

For ≤10-unit (≤0.10 mL) administrations during Weeks 1–4, consider using 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
Gently swirl or roll until fully dissolved (do not shake).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Advanced / Loading Phase (Optional)

Phase	Daily Dose (total blend)	Per-Peptide Dose	Units (mL)
Loading (Weeks 1–4)	1,500 mcg (1.5 mg)	~750 mcg each	22.5 units (0.225 mL)
Maintenance (Weeks 5–8)	1,000 mcg (1.0 mg)	~500 mcg each	15 units (0.15 mL)

Note: Advanced protocols consume peptide supplies faster. Plan vial quantities accordingly.

Plan based on a 12–24 week weekly protocol with gradual titration.

Plan based on a 4–8 week daily protocol (standard approach at ~1 mg/day maintenance).

Peptide Vials (BPC-157 + TB-500 20 mg Blend):
- 4 weeks (28 doses at ~0.67–1.0 mg/day): 2 vials
- 6 weeks (42 doses): 3 vials
- 8 weeks (56 doses): 3–4 vials
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 4 weeks: 28 syringes
- 6 weeks: 42 syringes
- 8 weeks: 56 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 4 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 6 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 4 weeks: 56 swabs → recommend 1 × 100-count box
- 6 weeks: 84 swabs → recommend 1 × 100-count box
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes

Concise summary of the once-weekly regimen.

Concise summary of the once-daily regimen.

Goal: Support tissue repair, wound healing, and musculoskeletal recovery in research contexts^[1]^[3].
Schedule: Daily subcutaneous injections for 4–8 weeks; some protocols include 3-month-on / 6-week-off cycling.
Dose Range: 500–1,500 mcg total blend daily (providing ~250–750 mcg of each peptide).
Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL total) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; use within 14 days^[6].

Suggested daily titration approach.

Start: 500–666 mcg total blend daily (~250–333 mcg each peptide).
Target: 1,000 mcg total blend daily (~500 mcg each) by Weeks 3–8.
Frequency: Once per day (subcutaneous).
Cycle Length: 4–8 weeks; optional cycling with 6-week breaks between courses.
Timing: Any consistent time; some prefer morning administration; rotate injection sites.

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure^[6].
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 14 days and avoid freeze-thaw cycles^[7].
Allow vials to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose properly in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and maintain absorption^[8].
Inject near the site of injury when targeting localized tissue repair (within anatomical reason).
Document daily dose and site rotation to maintain consistency.
Both BPC-157 and TB-500 are prohibited in competitive sports by WADA^[9].

BPC-157 is a synthetic pentadecapeptide (15 amino acids) originally isolated from human gastric juice. Preclinical research indicates it exerts cytoprotective effects across multiple organ systems, promotes angiogenesis, modulates nitric oxide pathways, and interacts with growth-factor systems involved in tissue repair^[1]^[2]. TB-500 (Thymosin β4) is a naturally occurring peptide that regulates actin polymerization, promotes cell migration, reduces inflammation, and supports wound healing and tissue regeneration^[3]^[4]. The combination is hypothesized to provide complementary mechanisms for accelerated musculoskeletal and soft-tissue recovery.

Observations from preclinical and early clinical literature.

Tissue Repair: Both peptides demonstrate wound-healing, tendon-repair, and anti-inflammatory properties in animal models^[1]^[3]^[10].
Gastrointestinal Support: BPC-157 shows gastroprotective and ulcer-healing effects in preclinical studies^[2].
Safety Profile: Preclinical data indicate a wide safety margin for BPC-157 (no lethal dose up to ~20 mg/kg); TB-500 human tolerability studies report mild adverse events at doses up to 1,260 mg^[5]^[11].
Possible Side Effects: Occasional mild injection-site reactions (redness, itching); rare reports of transient dizziness or nausea; long-term human safety data remain limited.

Complementary strategies for best outcomes.

Prioritize adequate protein intake to support tissue synthesis and repair.
Combine with appropriate rehabilitation protocols when addressing musculoskeletal injuries.
Ensure quality sleep and stress management to optimize recovery and healing responses.
Stay hydrated and maintain balanced micronutrient intake (vitamins C, D, zinc) to support connective-tissue health.

General subcutaneous guidance from clinical best-practice resources^[8]^[12].

Clean the vial stopper and injection site with alcohol; allow to dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (use 23–25 gauge, 5/8″ needle)^[12]^[13].
Aspiration is unnecessary for subcutaneous injections; inject slowly and steadily^[12].
Rotate sites systematically (abdomen, lateral thigh, upper arm, buttocks) to avoid lipohypertrophy^[8].
For localized injuries, inject subcutaneously near (not into) the affected area when anatomically appropriate.

This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Both BPC-157 and TB-500 are unapproved investigational peptides. Consult a qualified healthcare professional before considering any research application.

References

— Stable gastric pentadecapeptide BPC 157: pleiotropic beneficial activity and neurotransmitter interactions

— BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing and angiogenesis

— Thymosin β4: roles in development, repair, and regeneration

— Thymosin β4: a multi-functional regenerative peptide; basic mechanisms and clinical applications

— Thymosin beta 4 (Tb4) professional monograph (indications, dosage)

— Peptide stability and handling guidelines

— Evaluation of maximum beyond-use-date stability of peptide solutions

— Vaccine administration: subcutaneous route (angle, site rotation guidance)

— Growth factors and peptides prohibited in sport

— Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review

— Randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers

— Technique diagram and site guidance for subcutaneous injections

— Administration of parenteral medications: best practices

— Pharmacologic considerations of the subcutaneous route

— BPC-157 + TB-500 (20 mg Blend) product page (quality and batch documentation)

Mechanism Breakdown — 3rd Party Analysis

This video provides an external overview on WOLVERINE 20

External Source

Titration schedule.

Standard research titration model. Adjust under qualified clinical observation only. Not for human therapeutic use.

Phase 01

Wk 1 — 4

22.5 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

15 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

15 units

Once daily

Maintenance evaluation

Phase 04

Wk 13+

15 units

Once daily

Optional research extension

Research use only.

Reta20 is supplied strictly for in-vitro laboratory research and biochemical analysis. It is not intended for human consumption, diagnostic use, veterinary application or therapeutic administration of any kind.

Handling must be performed by qualified personnel in compliance with applicable institutional and jurisdictional safety standards. The information contained on this protocol sheet is provided for educational and reference purposes only and does not constitute medical advice.

Not for human use
Store at 2–8 °C, protected from light

Reconstitute under aseptic conditions
Document all research observations

Red Tier Catalogue

Explore the full British Dragon research line.

Premium-tier compounds engineered for serious metabolic, longevity and performance research programs.

WOLVERINE 20

BPC-157 + TB-500 (20mg Blend) Dosage Protocol

BPC-157 + TB-500 (20 mg Blend) Dosage Protocol

Table of Contents

Quickstart Highlights

Dosing & Reconstitution Guide

Standard / Gradual Approach (3 mL = ~6.67 mg/mL total)

Reconstitution Steps

Advanced / Loading Phase (Optional)

Supplies Needed

Protocol Overview

Dosing Protocol

Storage Instructions

Important Notes

How This Works

Potential Benefits & Side Effects

Lifestyle Factors

Injection Technique

Video

Important Note

References

Mechanism Breakdown — 3rd Party Analysis

Titration schedule.

Phase 01

Wk 1 — 4

22.5 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

15 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

15 units

Once daily

Maintenance evaluation

Phase 04

Wk 13+

15 units

Once daily

Optional research extension

Research use only.

Red Tier Catalogue

Explore the full British Dragon research line.